12/13/2022 5:45:12 AM
MediWound Signs Marketing And Distribution Deal With Bharat Serum And Vaccine For NexoBrid In India
9/20/2022 7:15:56 AM
Merck To Initiate New Phase 3 Clinical Program With Once-daily Islatravir For People With HIV-1 Infection
9/20/2022 7:09:02 AM
EMA Accepts MediWound’s Application For Extended Indication For NexoBrid For Pediatric Patients With Thermal Burns
7/11/2022 7:14:59 AM
MediWound Announces Positive Initial Data From U.S. Phase I/II Study Of MW005 For Basal Cell Carcinoma
7/7/2022 7:07:49 AM
MediWound Announces Positive Results From Phase 2 Pharmacology Study Of EscharEx
3/17/2022 7:24:40 AM
MediWound Q4 Loss Per Share $0.50 Vs Loss $0.34 Last Year
1/24/2022 6:06:33 AM
MediWound Announces Positive Topline Results From U.S. Phase 2 Trial Of EscharEx For Debridement Of Chronic Wounds